Studies have found that, in a mouse model of NASH, the CCR9/CCL25 axis promotes the recruitment of macrophages and the formation of fibrosis, providing a new potential therapeutic target for NASH (Morikawa et al., 2021). Here, CCL25 is linked to metabolic dysfunction-associated steatohepatitis.